Bridgewater Associates - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 409 filers reported holding HALOZYME THERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.

Quarter-by-quarter ownership
Bridgewater Associates ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q2 2024$1,739,452
+505.5%
33,221
+370.4%
0.01%
+800.0%
Q1 2024$287,282
+10.1%
7,0620.0%0.00%0.0%
Q4 2023$261,012
-3.2%
7,0620.0%0.00%
-50.0%
Q3 2023$269,768
-87.9%
7,062
-88.5%
0.00%
-85.7%
Q2 2023$2,221,73261,5950.01%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Third Security, LLC 14,092,771$206,177,00028.12%
BB BIOTECH AG 8,322,860$121,763,0003.90%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 398,633$4,579,0002.84%
DOHENY ASSET MANAGEMENT /CA 227,193$3,324,0002.43%
SNYDER CAPITAL MANAGEMENT L P 2,833,759$41,458,0002.24%
First Light Asset Management, LLC 938,399$13,729,0002.19%
IRIDIAN ASSET MANAGEMENT LLC/CT 9,027,164$132,067,0001.77%
Taylor Wealth Management Partners 204,277$2,989,0001.72%
Sterling Global Strategies LLC 22,000$321,860,0001.63%
Granite Investment Partners, LLC 988,939$14,468,0001.06%
View complete list of HALOZYME THERAPEUTICS INC shareholders